244 related articles for article (PubMed ID: 17299510)
1. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors.
Gould TD; Einat H; O'Donnell KC; Picchini AM; Schloesser RJ; Manji HK
Neuropsychopharmacology; 2007 Oct; 32(10):2173-83. PubMed ID: 17299510
[TBL] [Abstract][Full Text] [Related]
2. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta.
Silva R; Mesquita AR; Bessa J; Sousa JC; Sotiropoulos I; Leão P; Almeida OF; Sousa N
Neuroscience; 2008 Mar; 152(3):656-69. PubMed ID: 18291594
[TBL] [Abstract][Full Text] [Related]
3. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress.
Chiu CT; Scheuing L; Liu G; Liao HM; Linares GR; Lin D; Chuang DM
Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25548109
[TBL] [Abstract][Full Text] [Related]
4. Chronic lithium salt treatment reduces CRE/CREB-directed gene transcription and reverses its upregulation by chronic psychosocial stress in transgenic reporter gene mice.
Böer U; Cierny I; Krause D; Heinrich A; Lin H; Mayr G; Hiemke C; Knepel W
Neuropsychopharmacology; 2008 Sep; 33(10):2407-15. PubMed ID: 18046304
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of protein L-isoaspartyl methyltransferase expression by lithium is mediated by glycogen synthase kinase-3 inactivation and beta-catenin stabilization.
Lamarre M; Desrosiers RR
Neuropharmacology; 2008 Oct; 55(5):669-76. PubMed ID: 18582478
[TBL] [Abstract][Full Text] [Related]
6. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice.
Pan JQ; Lewis MC; Ketterman JK; Clore EL; Riley M; Richards KR; Berry-Scott E; Liu X; Wagner FF; Holson EB; Neve RL; Biechele TL; Moon RT; Scolnick EM; Petryshen TL; Haggarty SJ
Neuropsychopharmacology; 2011 Jun; 36(7):1397-411. PubMed ID: 21389981
[TBL] [Abstract][Full Text] [Related]
7. Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD; Picchini AM; Einat H; Manji HK
Curr Drug Targets; 2006 Nov; 7(11):1399-409. PubMed ID: 17100580
[TBL] [Abstract][Full Text] [Related]
8. Lithium prevents stress-induced reduction of vascular endothelium growth factor levels.
Silva R; Martins L; Longatto-Filho A; Almeida OF; Sousa N
Neurosci Lett; 2007 Dec; 429(1):33-8. PubMed ID: 17980489
[TBL] [Abstract][Full Text] [Related]
9. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades.
Wada A
J Pharmacol Sci; 2009 May; 110(1):14-28. PubMed ID: 19423950
[TBL] [Abstract][Full Text] [Related]
10. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results.
Bersudsky Y; Shaldubina A; Kozlovsky N; Woodgett JR; Agam G; Belmaker RH
Behav Pharmacol; 2008 May; 19(3):217-24. PubMed ID: 18469539
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium.
O'Brien WT; Harper AD; Jové F; Woodgett JR; Maretto S; Piccolo S; Klein PS
J Neurosci; 2004 Jul; 24(30):6791-8. PubMed ID: 15282284
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. possible new GSK-3beta therapies for bipolar disorders.
Kozikowski AP; Gaisina IN; Yuan H; Petukhov PA; Blond SY; Fedolak A; Caldarone B; McGonigle P
J Am Chem Soc; 2007 Jul; 129(26):8328-32. PubMed ID: 17552518
[TBL] [Abstract][Full Text] [Related]
13. IP3 accumulation and/or inositol depletion: two downstream lithium's effects that may mediate its behavioral and cellular changes.
Sade Y; Toker L; Kara NZ; Einat H; Rapoport S; Moechars D; Berry GT; Bersudsky Y; Agam G
Transl Psychiatry; 2016 Dec; 6(12):e968. PubMed ID: 27922641
[TBL] [Abstract][Full Text] [Related]
14. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3.
Gould TD; Chen G; Manji HK
Neuropsychopharmacology; 2004 Jan; 29(1):32-8. PubMed ID: 12942141
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
Gould TD; Manji HK
Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice.
O'Brien WT; Huang J; Buccafusca R; Garskof J; Valvezan AJ; Berry GT; Klein PS
J Clin Invest; 2011 Sep; 121(9):3756-62. PubMed ID: 21821916
[TBL] [Abstract][Full Text] [Related]
17. A beta-arrestin 2 signaling complex mediates lithium action on behavior.
Beaulieu JM; Marion S; Rodriguiz RM; Medvedev IO; Sotnikova TD; Ghisi V; Wetsel WC; Lefkowitz RJ; Gainetdinov RR; Caron MG
Cell; 2008 Jan; 132(1):125-36. PubMed ID: 18191226
[TBL] [Abstract][Full Text] [Related]
18. Lithium ameliorates open-field and elevated plus maze behaviors, and brain phospho-glycogen synthase kinase 3-beta expression in fragile X syndrome model mice.
Chen X; Sun W; Pan Y; Yang Q; Cao K; Zhang J; Zhang Y; Chen M; Chen F; Huang Y; Dai L; Chen S
Neurosciences (Riyadh); 2013 Oct; 18(4):356-62. PubMed ID: 24141459
[TBL] [Abstract][Full Text] [Related]
19. Lithium induces follicular atresia in rat ovary through a GSK-3β/β-catenin dependent mechanism.
Mirakhori F; Zeynali B; Tafreshi AP; Shirmohammadian A
Mol Reprod Dev; 2013 Apr; 80(4):286-96. PubMed ID: 23426897
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3beta/beta-catenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium.
Kaga S; Zhan L; Altaf E; Maulik N
J Mol Cell Cardiol; 2006 Jan; 40(1):138-47. PubMed ID: 16288908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
